A Study Of New Medicine (GSK 372475) For The Treatment Of Depression
A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/Day to 2.0 mg/Day) or Extended Release Venlafaxine XR (150 mg/Day to 225 mg/Day) Compared to Placebo in Adult s
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Queensland
-
Auchenflower, Queensland, Australia, 4066
- GSK Investigational Site
-
Kippa Ring, Queensland, Australia, 4021
- GSK Investigational Site
-
-
Victoria
-
Epping, Victoria, Australia, 3076
- GSK Investigational Site
-
Heidelberg West, Victoria, Australia, 3081
- GSK Investigational Site
-
-
-
-
-
Liège, Belgium, 4000
- GSK Investigational Site
-
Mont-Godinne, Belgium, 5530
- GSK Investigational Site
-
-
-
-
-
Burgas, Bulgaria, 8000
- GSK Investigational Site
-
Varna, Bulgaria, 9010
- GSK Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6L 5X8
- GSK Investigational Site
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 2H4
- GSK Investigational Site
-
-
Nova Scotia
-
Sydney, Nova Scotia, Canada, B1S 2E8
- GSK Investigational Site
-
Sydney, Nova Scotia, Canada, B1P 1C6
- GSK Investigational Site
-
-
Ontario
-
Burlington, Ontario, Canada, L7R 4E2
- GSK Investigational Site
-
Mississauga, Ontario, Canada, L5M 4N4
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2T 2N6
- GSK Investigational Site
-
-
-
-
-
Tallinn, Estonia, 10614
- GSK Investigational Site
-
Tartu, Estonia, 50417
- GSK Investigational Site
-
Voru, Estonia, 65620
- GSK Investigational Site
-
-
-
-
-
Kuopio, Finland, 70110
- GSK Investigational Site
-
Turku, Finland, 20100
- GSK Investigational Site
-
-
-
-
-
Arcachon, France, 33120
- GSK Investigational Site
-
Paris, France, 75012
- GSK Investigational Site
-
Toulouse, France, 31000
- GSK Investigational Site
-
-
-
-
Bayern
-
Muenchen, Bayern, Germany, 80333
- GSK Investigational Site
-
Unterhaching, Bayern, Germany, 82008
- GSK Investigational Site
-
Wuerzburg, Bayern, Germany, 97070
- GSK Investigational Site
-
-
Mecklenburg-Vorpommern
-
Schwerin, Mecklenburg-Vorpommern, Germany, 19053
- GSK Investigational Site
-
-
Niedersachsen
-
Westerstede, Niedersachsen, Germany, 26655
- GSK Investigational Site
-
-
-
-
-
Bangalore, India, 560010
- GSK Investigational Site
-
Chennai, India, 600003
- GSK Investigational Site
-
Hyderabad, India, 500 034
- GSK Investigational Site
-
Tirupati, India, 517507
- GSK Investigational Site
-
-
-
-
-
Bialystok, Poland, 15-879
- GSK Investigational Site
-
Gdansk, Poland, 80-282
- GSK Investigational Site
-
Lublin, Poland, 20-442
- GSK Investigational Site
-
Skorzewo, Poland, 60-185
- GSK Investigational Site
-
-
-
-
-
Bratislava, Slovakia, 826 06
- GSK Investigational Site
-
Michalovce, Slovakia, 071 01
- GSK Investigational Site
-
-
-
-
-
Observatory ,Cape Town, South Africa, 7925
- GSK Investigational Site
-
Somerset West, South Africa, 7140
- GSK Investigational Site
-
Somerset West, South Africa, 7500
- GSK Investigational Site
-
Vereeniging, South Africa, 1929
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Major depressive episode (MDE) associated with Major Depressive Disorder (DSM-IV-TR criteria)
- Duration of current episode is at least 12 weeks duration and less than 2 years
- Symptoms of decreased energy, pleasure, and interest
- Female subjects who agree to use acceptable methods of birth control throughout the study
Exclusion criteria:
- Current diagnosis of Panic Disorder, or symptoms of generalized anxiety or panic attacks that could interfere with their ability to complete the trial
- Symptoms of MDE better accounted for by another diagnosis
- Diagnosis of Bipolar, schizophrenia, other psychotic disorder(s), borderline or antisocial personality disorder, or dementia.
- Started psychotherapy within 3 months prior to the Screening
- Received electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior to screening
- Received psychoactive drugs within 4 weeks of randomization
- Positive urine drug screen or positive blood alcohol
- Suicidal risk or has had any previous suicide attempt, a family history of suicide attempt
- Positive pregnancy test
- History of seizure disorder, myocardial infarction (< 1yr), or unstable medical condition
- Failed to respond to an adequate course of pharmacotherapy of at least 2 different antidepressants
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
|
daily administration during the 10-week treatment phase
|
|
Experimental: GSK372475
flexible-dose design from GSK372475 1.0 mg/day to GSK372475 2.0 mg/day
|
daily administration during the 10-week treatment phase
|
|
Active Comparator: Venlafaxine
Flexible- dose design from Venlafaxine XR 75 mg/day to Venlafaxine XR 225 mg/day
|
daily administration during the 10-week treatment phase
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from randomization to the end of the Treatment Phase (Week 10) on a depression rating scale.
Time Frame: Randomisation (week 0) And end of the treatment
|
Randomisation (week 0) And end of the treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Endpoints related to response & remission on depression rating scales during time of treatment exposureChange during treatment & at endpoint-week 10:in Clinical Global Impression scale; in motivation, energy, & sexual functioning on patient-rated scales
Time Frame: Randomisation (week 0) and at weeks 1,2,4,6,8 and week 10 (end of treatment phase)
|
Randomisation (week 0) and at weeks 1,2,4,6,8 and week 10 (end of treatment phase)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Serotonin and Noradrenaline Reuptake Inhibitors
- Venlafaxine Hydrochloride
Other Study ID Numbers
Other Study ID Numbers
- SND 103285
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.